Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol Rapid Up-Titration in HFrEF
NCT05179070Phase 4Unknown
- Sponsor
- Universitas Sebelas Maret
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial of carvedilol in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Universitas Sebelas Maret. Primary endpoints: Interleukin-6 at 1 month, Tumor Necrosis Factor-alpha at 1 month and 5 more. Status: unknown.
02
Drugs
carvedilol
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05179070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179070.